-

12:02:45 PM

JAGX Stock News

JAGX - Jaguar Health Inc

11/19/21 9:20 AM

Nasdaq : JAGX

clinical trial

Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients

Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention

RHEA-AI

neutral

11/17/21 8:00 AM

Nasdaq : JAGX

earnings

Jaguar Health Reports 2021 Third Quarter Financial Results

Mytesi ® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to complete transition to selling Mytesi through closed specialty pharmacy network by end of 2021 as part

RHEA-AI

neutral

11/16/21 8:30 AM

Nasdaq : JAGX

management

Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager

Jaguar Health, Inc. (NASDAQ:JAGX) today announced the

RHEA-AI

positive

11/15/21 7:00 AM

Nasdaq : JAGX

Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's investor webcast to review third-quarter 2021 financials and provide business updates

RHEA-AI

neutral

11/10/21 8:30 AM

Nasdaq : JAGX

conferences

Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, November 15, 2021 at 8:30 a.m. Eastern Time to

RHEA-AI

neutral

11/08/21 8:30 AM

Nasdaq : JAGX

management

Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer

Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief regulatory officer. A recognized expert in global regulatory affairs, Ms. Amatulli will be

RHEA-AI

neutral

11/02/21 8:30 AM

Nasdaq : JAGX

Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch

Jaguar Health, Inc. (NASDAQ:JAGX) today

RHEA-AI

positive

11/01/21 8:30 AM

Nasdaq : JAGX

acquisition

The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU S.p.A. and Dragon SPAC S.p.A. has closed. "We know shareholders and other stakeholders have been

RHEA-AI

neutral

10/29/21 4:15 PM

Nasdaq : JAGX

management

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021, the Company granted nonstatutory stock options for the purchase of up to 2,666 shares of the Company's common stock to New Employee 1

RHEA-AI

very positive

10/25/21 8:30 AM

Nasdaq : JAGX

acquisition

Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing

Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front license fee due to Jaguar Napo EU S.p.A.'s initial focus is on the conditional marketing authorization

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

JAGX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitejaguar.health
CeoLisa Conte
Security nameJaguar Health Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees34
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address200 Pine Street Suite 400
StateCalifornia
CitySan Francisco
Zip94104
CountryUS
Phone14153718300

JAGX Description:

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Its Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.